How Does the World's First Robot with Closed System Transfer Device Work?
The industry has accepted that CSTDs were created to prevent deficiencies that exist when compounding with needles and syringes, including the escape of hazardous drug via leakage, aerosol, and vapor.
LAS VEGAS — Officials with Equashield unveiled the world's first robot with closed system transfer device (CSTD), dubbed the Equashield® Pro, at the ASHP Midyear Meeting held here earlier this month.
According to a prepared statement from the manufacturer, Equashield® Pro enables compounding of a large variety of patient specific chemotherapy doses quickly, using a method of compounding that shortens the process flow while performing multiple tasks. Equashield® Pro's dose verification software reduces the occurrences of medication dosage and identification errors in hospitals.
Equashield® Pro is designed around Equashield's proprietary CSTD technology, which simplifies the overall robot design and increases throughput. The industry has accepted that CSTDs were created to prevent deficiencies that exist when compounding with needles and syringes, including the escape of hazardous drug via leakage, aerosol, and vapor. See it in action below.
"Equashield Pro also means that healthcare workers are now protected by Equashield CSTDs from the compounding stage all the way through the administration of these drugs to patients, in-line with the upcoming USP800 guidelines," explained Marino Kriheli, founder of Equashield, in the prepared statement.
At the meeting, reactions to the robot were positive, with one attendee having this to say about the technology:
